| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,285 | 1,855 | 18.11. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | BPC INSTRUMENTS AB: BPC Instruments partners with limu.eco to evaluate additives for biodegradable plastics | 1 | Cision News | ||
| 26.08. | BPC Instruments AB (publ) reports results for H1 and Q2 2026 | 2 | Cision News | ||
| 10.06. | BPC INSTRUMENTS AB: BPC Instruments receives ISO 9001 certification for quality management | 1 | Cision News | ||
| 26.05. | Bulletin from the Annual General Meeting of BPC Instruments AB (publ) | 1 | Cision News | ||
| 19.05. | BPC Instruments AB: BPC Instruments partners with AURI on anaerobic digestion experimentation in the United States | 879 | PR Newswire | LUND, Sweden, May 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) ("BPC") has entered a strategic collaboration with the Agricultural Utilization Research Institute ("AURI") to improve... ► Artikel lesen | |
| 26.02. | BPC Instruments AB: BPC Instruments reports results for 2025 | 723 | PR Newswire | LUND, Sweden, Feb. 26, 2026 /PRNewswire/ -- BPC Instruments AB (publ) hereby publishes the year-end report for the year 2025. The year-end report is available as... ► Artikel lesen | |
| 24.02. | BPC Instruments AB: BPC Instruments receives two repeat orders from Denmark within biogas applications | 949 | PR Newswire | LUND, Sweden, Feb. 24, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received two repeat orders from Denmark within biogas applications with a total value of approximately SEK 1.1 million.... ► Artikel lesen | |
| 19.02. | BPC Instruments AB: BPC Instruments secures order for BPC Blue system from global testing and certification group | 681 | PR Newswire | LUND, Sweden, Feb. 19, 2026 /PRNewswire/ -- BPC Instruments AB (publ) has received an order valued at approximately SEK 0.8 million for BPC's most advanced BPC Blue configuration, including... ► Artikel lesen | |
| BPC INSTRUMENTS Aktie jetzt für 0€ handeln | |||||
| 16.12.25 | BPC Instruments AB: BPC Instruments partners with SixRing to provide quality assurance for the EU and UK biomethane markets | 700 | PR Newswire | LUND, Sweden, Dec. 16, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has entered into a collaboration with SixRing, the Canadian technology company behind Stimulose, a new feedstock additive... ► Artikel lesen | |
| 20.11.25 | BPC Instruments AB: BPC Instruments secures new order for several BPC Go units from a international energy group | 679 | PR Newswire | LUND, Sweden, Nov. 20, 2025 /PRNewswire/ -- BPC Instruments AB (publ) has received a new order valued at approximately SEK 0.9 million for several BPC Go units from a major international... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |